US2014341911A1PendingUtilityA1
Prevention and Treatment of Amyloidogenic Disease
Assignee: JANSSEN ALZHEIMER IMMUNOTHERAPPriority: Dec 2, 1997Filed: Jan 2, 2014Published: Nov 20, 2014
Est. expiryDec 2, 2017(expired)· nominal 20-yr term from priority
Inventors:Dale B. Schenk
A61P 25/00A61P 25/28A61K 2039/55555A61K 38/193A61K 39/0005C07K 16/18A61K 39/0007A61K 2039/55505C07K 14/4711A61K 2039/505C07K 2317/77A61K 2039/605C07K 2317/70A61K 38/1709C07K 2317/34A61K 2039/53A61K 2039/6037A61K 2039/55577A61K 2039/55572G01N 2800/2821A61K 2039/55566C07K 2319/00A61K 39/00C07K 2316/95A61K 39/395Y02A50/30
64
PatentIndex Score
0
Cited by
0
References
0
Claims
Abstract
The invention provides compositions and methods for treatment of amyloidogenic diseases. Such methods entail administering an agent that induces a beneficial immune response against an amyloid deposit in the patient. The methods are particularly useful for prophylactic and therapeutic treatment of Alzheimer's disease. In such methods, a suitable agent is Aβ peptide, active fragments thereof or an antibody thereto.
Claims
exact text as granted — not AI-modified1 . A method of preventing or treating a disease characterized by amyloid deposit in a patient, comprising administering an effective dosage of an antibody that specifically binds to the amyloid deposit or a component thereof to the patient.
2 - 37 . (canceled)
38 . A method of preventing or treating Alzheimer's disease, comprising administering an effective dosage of a polypeptide comprising an active fragment of Aβ that induces an immune response to Aβ in the patient.
39 - 52 . (canceled)
53 . A pharmaceutical composition comprising an active fragment of Aβ effective to induce a response to AB in a patient and an adjuvant.
54 - 55 . (canceled)Join the waitlist — get patent alerts
Track US2014341911A1 — get alerts on status changes and closely related new filings.
We store only your email — no account needed. See our privacy policy.